Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Feb 21, 2024 10:04am

160 Views

Post# 35890710

RE:RE:New Press Release - Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

The revenue guidance is back end loaded,,,,I hope the softer sales in the first and second quarter do not show negative comps.

Another 5 million$ in Oncology in the first half of the year then ZERO ....So THTX needs to find a partner before then....

Still a messy situation but less dire than 4 mos ago

palinc2000 wrote: Financial statements not yet posted in the website..
However tthe Going Concern wording is still there,,,Marathon still is big overhang even though tranches 3 and 4 have not and will not be disbursed....
Nothing on efficacy of Th 1902 and nothing on potential partnership
Only silver lining is Ebitda guidance